Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study

NCT02402998 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT02402998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02402998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2016
Completion date
August 28, 2019
Enrollment
55 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

primacy immune thrombocytopenia